The real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's Vyalev ...
AbbVie’s ROSSINI (NCT06107426) study of its Parkinson’s disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which was presented on 29 June at the 12 th Congress of the ...
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...
What has made the biggest impact on dentistry and dental practice today? This Collection reflects the issues that really matter to practising dentists and are some of the recent hottest topics from ...
As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead – aligning innovation with access drivers and gaining a ...
AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and addressing future patent cliffs proactively. Skyrizi and Rinvoq have already replaced Humira's revenue, ...
The Green Bay Packers today announced the dates of practices that are open to the public for the 2026 Packers Training Camp, presented by UW Health Kids. This marks Green Bay's 81st training camp, a ...
Pump delivered therapy can help some people ease their Parkinson’s symptoms, especially when a type of medications begins to wear off and symptoms worsen or reappear. A longtime dream for many living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results